Seyahi E, Ozdogan H, Masatlioglu S, Yazici H
Department of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Turkey.
Clin Exp Rheumatol. 2002 Jul-Aug;20(4 Suppl 26):S43-4.
Colchicine is the treatment of choice in familial Mediterranean fever (FMF) both for attacks and for prevention of secondary amyloidosis. The overall non-responder rate varies from 5-10 to 40%. Thalidomide is known to blunt the acute phase response. We report the efficacy of the addition of thalidomide to colchicine in controlling the febrile attacks and acute phase response in a patient with FMF resistant to 2 mg colchicine per day.
秋水仙碱是家族性地中海热（FMF）发作期及预防继发性淀粉样变性的首选治疗药物。总体无反应率在5% - 10%至40%之间。已知沙利度胺可抑制急性期反应。我们报告了在一名对每日2毫克秋水仙碱耐药的FMF患者中，加用沙利度胺至秋水仙碱治疗方案后，在控制发热发作及急性期反应方面的疗效。
